Halozyme Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan. And we're continuing the 2021 health care conference today with Halozyme. This year is a little different. So I'm sort of going across the hall for the breakout session. (Operator Instructions)
But without further delay, let me turn it over to Halozyme's CEO, Helen Torley.
Thank you, Jess, and thank you, everybody, for joining us today. 2020 was a year of remarkable progress and accomplishments at Halozyme. While we'll give our 2020 financial results in February, I'm pleased to report that we expect our revenues to be within the guidance range of $265 million to $275 million, which represents at least 35% growth year-over-year, and we expect our earnings per share to be in the range of $0.90 to $0.95, which was our -- also our updated guidance. Now this great performance was driven by the ongoing progress in our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
